Is PLX4032 the future of melanoma treatment?
Is PLX4032 the future of melanoma treatment? Tuesday February 23, 2010 The New York Times has an interesting article today looking at the effect of a cancer drug called PLX4032, which is currently being tested on melanoma patients. The drug, which targets a specific gene mutation that drives cancer growth, has been shown to shrink tumors by more than 30% in 9 of the 16 melanoma patients in the phase 1 trial. However, it will take much more research before this treatment option is widely available. You can read more about the specific outcomes of the PLX4032 trial in this Medical News Today article. Comments are closed for this post. See All Posts